US OptionsDetailed Quotes
ORGS250221P7500
- 0.00
- 0.000.00%
15min DelayClose Dec 26 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV-158.62%PremiumFeb 21, 2025Expiry Date4.60Intrinsic Value100Multiplier56DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Orgenesis Stock Discussion
Orgenesis: Nasdaq to Delist Co 's Common Stock, Securities Trading Will Be Suspended on Oct 21
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard.
On October 17, 2024, the Nasdaq Stock Market LLC (“Nasdaq”) notified Orgenesis Inc. (the “Company”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common stock and that trading of the Company’s securities will be suspended at the open of trading on October 21, 2024.
$CN Energy (CNEY.US)$ $Taoping (TAOP.US)$ $Alset (AEI.US)$ $Ambipar Emergency Response (AMBI.US)$ $Knightscope (KSCP.US)$ $Orgenesis (ORGS.US)$ $ShiftPixy (PIXY.US)$ $Aurora Mobile (JG.US)$ $CN Energy (CNEY.US)$
📊⚡️📊
Orgenesis Inc: Data Indicate a Potentially Favorable Safety Profile With a Lower Incidence of Cytokine Release Syndrome
Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia
Orgenesis (NASDAQ: ORGS) announced positive results from a real-world study of its CD19 CAR-T therapy, ORG-101, in patients with CD19+ Acute Lymphoblastic Leukemia. The study showed complete response rates of 82% in adults and 93% in pediatric patients, with low incidence of severe Cytokine Release Syndrome (2% in adults, 6% in pediat...
No comment yet